Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Revolution Beauty cancels sale, brings back founders to lead 'strategic reset'

(Sharecast News) - Revolution Beauty has terminated its sale process and announced a proposed fundraising to raise £16.5m, as it brings back its co-founders to lead a "strategic reset" to turn the business around - which includes sweeping redundancies. The news comes as the loss-making makeup, skincare and hair products manufacturer reported that sales over the year to 28 February were down by a quarter due to a lack of revenues from discontinued products amid a planned rationalisation of its product and brand portfolio.

Revolution said that, having not received an adequate proposal for the company since its formal sales process kicked off in May, it has terminated all talks with third parties and cancelled the formal sales process.

Instead, the company aims to raise £15m via a proposed placing and subscription, as well as £1.5m from a proposed retail offer.

At the same time, co-founder Tom Allsworth has been appointed as CEO, with interim boss Colin Henry stepping down with immediate effect, to lead a "revised and rebalanced business plan to set a clear path back to growth and long-term value creation", Revolution said. Fellow co-founder Adam Minto will also return to the business in a consultancy role.

The company said it wants to return to its "original formula for success - fast, trend-driven innovation combined with a product-led strategy". A key element of the plan will be reducing the company's cost base, which includes cutting £7.5m in annual staff costs through a "material reduction of headcount" across geographies and business functions.

"Revolution Beauty is a great brand, but the business has lost its way. We are confident that with a return to the founder-led management team who originally scaled the brand, there is a clear path back to growth and long-term value creation," said chair Iain McDonald.

Revenues totalled just £142.6m over the last fiscal year, down 25.5% from £191.3m the year before, with adjusted EBITDA slumping 62.7% to £4.7m and statutory pre-tax losses totalled £16.8m, compared with a profit of £11.4m previously.

The results followed an 8.0 percentage point collapse in the gross margin to 38.2% after the significant impact from the planned clearance of non-core inventory.

Since the year-end, sales fell by 29% over the first quarter and by an estimated 25% over the second quarter, when compared with last year.

Shares were up nearly 9% at 3.8p by 0807 BST, having slumped by more than 80% so far this year.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.